Aerovate Therapeutics IPO

2/17/2022

IPO

$121,800,000

We currently expect to use our net proceeds from this offering to: fund further development of AV-101 through completion of the Phase 2b portion and the data read out of the Phase 3 portion of our global Phase 2b/3 clinical trial; to fund continued chemistry, manufacturing and controls work for AV-101; to fund expenses related to pursuing a commercial launch of AV-101; and to use the remainder, if any, for working capital and general corporate purposes, which may include the hiring of additional personnel, capital expenditures and the costs of operating as a public company.

Publicly-held

Biopharmaceutical

200 Berkeley St. 18th Floor
Boston, MA 02116
USA

Aerovate Therapeutics is a biotechnology company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease. Aerovate's lead program is a potentially disease modifying drug, AV-101, for people who suffer from pulmonary arterial hypertension (PAH).